Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.
A drop-off in virulence is possible for the SARS-CoV-2 virus – once enough of the global population has been vaccinated or exposed to it, according to a study from scientists at Emory University and The Pennsylvania State University.
Evidence continues to build for long-lasting immunity to Covid-19 following disease infection, with the publication of a new study showing a durable immune response as far as eight months after the initial onset of symptoms.
In a paper published in Alzheimer’s and Dementia, a team of researchers called for more prospective studies that will look into the impact COVID-19 has on brain functioning, given the disease has been frequently associated with neurologic symptoms such as seizures and psychosis.
The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
A review of recently published scientific studies includes a detailed imaging analysis to determine how SARS-CoV-2, the virus that causes Covid-19, reprograms infected cells.
A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
The Covid-19-causing coronavirus is mutating while spreading around the world in the pandemic, but none of the mutations currently documented appears to be making the SARS-CoV-2 virus able to spread more rapidly, scientists said.